Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial

Journal of Hepatology

Volumn 65, Issue 1, 2016, Pages 33-39

  Younossi, Zobair M ^a,h,i   Stepanova, Maria ^b   Feld, Jordan ^c   Zeuzem, Stefan ^d   Jacobson, Ira ^e   Agarwal, Kosh ^f   Hezode, Christophe ^g   Nader, Fatema ^b   Henry, Linda ^b   Hunt, Sharon ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Center for Outcomes Research in Liver Diseases   (United States)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e BETH ISRAEL MEDICAL CENTER   (United States)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g HENRI MONDOR HOSPITAL   (France)

^h BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

ⁱ Betty and Guy Beatty Center for Integrated Research   (United States)

Author keywords

HCV; PRO; SOF VEL

Indexed keywords

PLACEBO; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; RIBAVIRIN; SOFOSBUVIR; VELPATASVIR;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENERAL CONDITION IMPROVEMENT; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT WORRY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; WELLBEING; HEPACIVIRUS; PATIENT-REPORTED OUTCOME; QUALITY OF LIFE;

ANTIVIRAL AGENTS; CARBAMATES; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; RIBAVIRIN; SOFOSBUVIR;

EID: 84964678998     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.02.042     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep 61 2012 1 18
2. V.A. Moyer U.S. Preventive Services Task Force Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 159 2013 349 357
3. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
4. H.B. El-Serag Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 2012 1264 1273 e1
5. M. Stepanova, H. Wai, S. Saab, A. Mishra, C. Venkatesan, and Z.M. Younossi The portrait of an adult liver transplant recipient in the United States from 1987 to 2013 JAMA Intern Med 174 2014 1407 1409
6. I.M. Jacobson, P. Cacoub, L. Dal Maso, S.A. Harrison, and Z.M. Younossi Manifestations of chronic hepatitis C virus infection beyond the liver Clin Gastroenterol Hepatol 8 2010 1017 1029
7. Z.M. Younossi, F. Kanwal, S. Saab, K.A. Brown, H.B. El-Serag, W.R. Kim, and et al. The impact of hepatitis C burden: an evidence-based approach Aliment Pharmacol Ther 39 2014 518 531
8. H. Razavi, A.C. Elkhoury, E. Elbasha, C. Estes, K. Pasini, T. Poynard, and et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States Hepatology 57 2013 2164 2170
9. B.M. Spiegel, Z.M. Younossi, R.D. Hays, D. Revicki, S. Robbins, and F. Kanwal Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment Hepatology 41 2005 790 800
10. J. Kallman, M.M. O'Neil, B. Larive, N. Boparai, L. Calabrese, and Z.M. Younossi Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection Dig Dis Sci 52 2007 2531 2539
11. L. Kleinman, S. Mannix, Y. Yuan, S. Kummer, G. L'Italien, and D. Revicki Review of patient-reported outcome measures in chronic hepatitis C Health Qual Life Outcomes 7 2012 92
12. Z.M. Younossi, M. Stepanova, L. Henry, E. Gane, I.M. Jacobson, E. Lawitz, and et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C) J Hepatol 60 2014 741 747
13. Z.M. Younossi, M. Stepanova, L. Henry, E. Gane, I.M. Jacobson, E. Lawitz, and et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C Clin Gastroenterol Hepatol 12 2014 1349 1359 e13
14. Z. Younossi, J. Kallman, and J. Kincaid The effects of HCV infection and management on health-related quality of life Hepatology 45 2007 806 816
15. J.G. McHutchison, J.E. Ware Jr, M.S. Bayliss, S. Pianko, J.K. Albrecht, S. Cort, et al. Hepatitis Interventional Therapy Group The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity J Hepatol 34 2001 140 147
16. Z.M. Younossi, M. Stepanova, L. Henry, F. Nader, and S.L. Hunt Interferon (IFN), Ribavirin (RBV), duration of treatment and baseline Patient-Reported Outcomes (PROs) predict adherence to the new regimens for treatment of Chronic Hepatitis C (CH-C) Hepatology 62 2015 371A
17. Z. Younossi, and L. Henry Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens Aliment Pharmacol Ther 41 2015 497 520 10.1111/apt.13090 [Epub 2015 Jan 23. Review]
18. Z.M. Younossi, M. Stepanova, L. Henry, F. Nader, and S. Hunt An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens Am J Gastroenterol 2016 10.1038/ajg.2016.99 [Epub ahead of print]
19. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, R.H. Hyland, and et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
20. P. Andreone, M.G. Colombo, J.V. Enejosa, I. Koksal, P. Ferenci, A. Maieron, and et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection Gastroenterology 147 2014 359 365 (PEARL II)
21. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, K. Agarwal, and et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982 (TURQUOISE II)
22. S. Zeuzem, I.M. Jacobson, T. Baykal, R.T. Marinho, F. Poordad, M. Bourlière, and et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1604 1614 (SAPPHIRE II)
23. E. Lawitz, M.S. Sulkowski, R. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, A. Corregidor, and et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384 2014 1756 1765
24. N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, M. Puoti, and et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
25. N. Afdhal, K.R. Reddy, D.R. Nelson, E. Lawitz, S.C. Gordon, E. Schiff, and et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
26. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, E. Lawitz, and et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
27. D.R. Nelson, J.N. Cooper, J.P. Lalezari, E. Lawitz, P.J. Pockros, N. Gitlin, and et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study Hepatology 61 2015 1127 1135
28. M.A. Smith, R.E. Regal, and R.A. Mohammad Daclatasvir: A NS5A replication complex inhibitor for hepatitis C infection Ann Pharmacother 50 2016 39 46
29. Z.M. Younossi, M. Stepanova, L. Henry, E. Gane, I.M. Jacobson, E. Lawitz, and et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C Clin Gastroenterol Hepatol 12 2014 1349 1359 e13
30. Z.M. Younossi, M. Stepanova, S. Zeuzem, G. Dusheiko, R. Esteban, C. Hezode, and et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study J Hepatol 61 2014 228 234
31. Z.M. Younossi, M. Stepanova, F. Nader, I.M. Jacobson, E. Gane, D. Nelson, and et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens Hepatology 59 2014 2161 2169
32. Z.M. Younossi, M. Stepanova, N. Afdhal, K.V. Kowdley, S. Zeuzem, L. Henry, and et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir J Hepatol 63 2015 337 345
33. Z.M. Younossi, M. Stepanova, S. Pol, J.P. Bronowicki, M.P. Carrieri, and M. Bourlière The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study Liver Int 36 2016 42 48
34. Z.M. Younossi, M. Stepanova, M. Sulkowski, S. Naggie, M. Puoti, C. Orkin, and et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes J Infect Dis 212 2015 367 377
35. Z.M. Younossi, M. Stepanova, P. Marcellin, N. Afdhal, K.V. Kowdley, S. Zeuzem, and et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials Hepatology 61 2015 1798 1808
36. Z.M. Younossi, M. Stepanova, F. Nader, B. Lam, and S. Hunt The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life Aliment Pharmacol Ther 42 2015 286 295
37. M. Vera-Llonch, M. Martin, J. Aggarwal, M. Donepudi, M. Bayliss, T. Goss, and et al. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study Aliment Pharmacol Ther 38 2013 124 133
38. J. Aggarwal, M. Vera-Llonch, M. Donepudi, E. Suthoff, Z. Younossi, and T.F. Goss Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment J Viral Hepat 22 2015 8 17
39. Z. Younossi, and L. Henry Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens Aliment Pharmacol Ther 41 2015 497 520
40. D.A. Redelmeier, and V.M. Dickinson Determining whether a patient is feeling better: pitfalls from the science of human perception J Gen Intern Med 26 2011 900 906
41. J.J. Feld, I.M. Jacobson, C. Hézode, T. Asselah, P.J. Ruane, N. Gruener, and et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection N Engl J Med 373 2015 2599 2607
42. J.E. Ware, and M. Kosinski Interpreting SF-36 summary health measures: a response Qual Life Res 10 2001 405 413
43. K. Webster, L. Odom, A. Peterman, L. Lent, and D. Cella The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire Qual Life Res 8 1999 604
44. Z.M. Younossi, G. Guyatt, M. Kiwi, N. Boparai, and D. King Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease Gut 45 1999 295 300
45. M.C. Reilly, A.S. Zbrozek, and E.M. Dukes The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 4 1993 353 365
46. L. Gerber, M. Estep, M. Stepanova, C. Escheik, A. Weinstein, and Z.M. Younossi Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection Clin Gastroenterol Hepatol 14 2016 156 164 e3
47. S. Monaco, S. Mariotto, S. Ferrari, M. Calabrese, G. Zanusso, A. Gajofatto, and et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015 World J Gastroenterol 21 2015 11974 11983
48. V. Byrnes, A. Miller, D. Lowry, E. Hill, C. Weinstein, D. Alsop, and et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition J Hepatol 56 2012 549 556
49. R. Two, A. Verjee-Lorenz, D. Clayson, M. Dalal, K. Grotzinger, and Z.M. Younossi A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries Value Health 13 2010 128 131